Neurocrine Biosciences (LTS:0K6R) Cyclically Adjusted FCF per Share: $2.95 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K6R Neurocrine Biosciences Inc LTS:0K6R
94 GF Score
Price $166.30
GF Value $192.89
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Cyclically Adjusted FCF per Share?

Neurocrine Biosciences LTS:0K6R -7.69% 94 Cyclically Adjusted FCF per Share is $2.95 as of Jun. 2026. GuruFocus rates LTS:0K6R with a GF Score™ of 94/100 and a GF Value™ of $192.89 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Neurocrine Biosciences's adjusted free cash flow per share for the three months ended in Jun. 2026 was $1.234. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $2.95 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Neurocrine Biosciences's average Cyclically Adjusted FCF Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 62.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Neurocrine Biosciences was 110.10% per year. The lowest was -15.90% per year. And the median was 12.50% per year.

As of today (2026-08-01), Neurocrine Biosciences's current stock price is $166.30. Neurocrine Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $2.95. Neurocrine Biosciences's Cyclically Adjusted Price-to-FCF of today is 56.37.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Neurocrine Biosciences was 3350.67. The lowest was 46.60. And the median was 136.55.


Neurocrine Biosciences  (LTS:0K6R) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Neurocrine Biosciences's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=166.30/2.95
=56.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Neurocrine Biosciences was 3350.67. The lowest was 46.60. And the median was 136.55.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Neurocrine Biosciences Cyclically Adjusted FCF per Share Related Terms


Neurocrine Biosciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Cyclically Adjusted FCF per Share Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.59 1.03 1.67 2.51

Neurocrine Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.88 2.10 2.51 2.77 2.95

LTS:0K6R vs VTRS, UTHR, ELAN: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted Price-to-FCF falls into.


LTS:0K6R
94GF Score
Neurocrine Biosciences Inc LTS:0K6R
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Neurocrine Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.234/333.9520*333.9520
=1.234

Current CPI (Jun. 2026) = 333.9520.

Neurocrine Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.366 241.428 -0.506
201612 -0.368 241.432 -0.509
201703 -0.902 243.801 -1.236
201706 -0.552 244.955 -0.753
201709 -0.137 246.819 -0.185
201712 0.431 246.524 0.584
201803 -0.450 249.554 -0.602
201806 0.176 251.989 0.233
201809 0.584 252.439 0.773
201812 0.465 251.233 0.618
201903 -1.278 254.202 -1.679
201906 0.630 256.143 0.821
201909 0.981 256.759 1.276
201912 0.974 256.974 1.266
202003 0.353 258.115 0.457
202006 1.163 257.797 1.507
202009 -0.223 260.280 -0.286
202012 0.926 260.474 1.187
202103 0.843 264.877 1.063
202106 1.012 271.696 1.244
202109 0.574 274.310 0.699
202112 -0.048 278.802 -0.057
202203 -0.493 287.504 -0.573
202206 1.353 296.311 1.525
202209 1.015 296.808 1.142
202212 1.402 296.797 1.578
202303 -1.377 301.836 -1.524
202306 1.725 305.109 1.888
202309 2.022 307.789 2.194
202312 1.156 306.746 1.259
202403 1.150 312.332 1.230
202406 0.510 314.175 0.542
202409 1.437 315.301 1.522
202412 2.288 315.605 2.421
202503 0.528 319.799 0.551
202506 0.886 322.561 0.917
202509 2.091 324.800 2.150
202512 3.758 324.054 3.873
202603 1.322 330.213 1.337
202606 1.234 333.952 1.234

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $2.95 mean?
Neurocrine Biosciences (LTS:0K6R) has a Cyclically Adjusted FCF per Share of $2.95 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Cyclically Adjusted FCF per Share too high?
Neurocrine Biosciences' current Cyclically Adjusted FCF per Share is $2.95. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Cyclically Adjusted FCF per Share compare to VTRS and UTHR?
Neurocrine Biosciences' Cyclically Adjusted FCF per Share of $2.95 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Cyclically Adjusted FCF per Share is $2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Modestly Undervalued. The stock's GF Value™ is $192.89, compared to a current price of $166.30 — trading 13.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $2.95. Neurocrine Biosciences' overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current Cyclically Adjusted FCF per Share is $2.95 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of $166.30 is trading 13.8% below its estimated GF Value™ of $192.89. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for LTS:0K6R:

  • Cyclically Adjusted FCF per Share: $2.95
  • GF Value™: $192.89 vs. price of $166.30 (13.8% below fair value)
  • GF Score™: 94/100 with 4 warning signs

No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for LTS:0K6R

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$166.30
Price
$192.89
GF Value